Skip to main content
TrustRadius
CalciMedica

CalciMedica

Overview

What is CalciMedica?

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief…

Read more
Recent Reviews
TrustRadius

Leaving a review helps other professionals like you evaluate Clinical Data Management Systems

Be the first one in your network to review CalciMedica, and make your voice heard!

Return to navigation

Pricing

View all pricing
N/A
Unavailable

What is CalciMedica?

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific…

Entry-level set up fee?

  • No setup fee

Offerings

  • Free Trial
  • Free/Freemium Version
  • Premium Consulting/Integration Services

Would you like us to let the vendor know that you want pricing?

Alternatives Pricing

What is Petofy OPHR?

A Cloud Based Veterinary Software secured with Microsoft Azure that is organized for managing the whole clinic for vets. Its features include adding pets, generating their clinical visits/x-ray reports/surgeries and hospitalizations, generating immunization reports (both automatic and manual…

Return to navigation

Product Details

What is CalciMedica?

CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases.

The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs.

The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.

CalciMedica Technical Details

Operating SystemsUnspecified
Mobile ApplicationNo
Return to navigation

Comparisons

View all alternatives
Return to navigation

Reviews

Sorry, no reviews are available for this product yet

Return to navigation